Search Results

You are looking at 171 - 180 of 375 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Reimagining Cancer Staging in the Era of Evolutionary Oncology

Kedar S. Kirtane, Mohammad U. Zahid, Heiko Enderling, and Louis B. Harrison

response to radiation therapy and evaluate altered fractionation in head and neck cancer . Appl Radiat Oncol 2021 ; 10 : 32 – 39 . 11. Bruno R , Bottino D , de Alwis DP , Progress and opportunities to advance clinical cancer therapeutics

Full access

Cancer Patient Survival and Erythropoietin

John A. Glaspy

; 108 : 39 – 40 . 15 Semenza GL . HIF-1 and tumor progression: pathophysiology and therapeutics . Trends Mol Med 2002 ; 8 [ suppl 4 ]: S62 – S67 . 16 Vaupel P Briest S Hockel M . Hypoxia in breast cancer: pathogenesis

Full access

Biosimilars: Approval and Acceptance?

Jessica K. DeMartino

ability to substitute biosimilars that have been deemed interchangeable, many pharmacists and Pharmacy and Therapeutics (P&T) Committees many not be comfortable with automatic substitution for these biosimilars. Pharmacists and P&T Committees may perform

Full access

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price

Daniel Tobias Michaeli and Thomas Michaeli

their focus on the first 5 years after the program was signed into law—many of the analyzed therapeutics receiving the BTD in late clinical development could not benefit from all the advantages of the program. Furthermore, Hwang et al 12 focused only on

Full access

NCCN News

their participation on Pharmacy & Therapeutics Committees for hospitals and managed care organizations, where they are often responsible for performing literature reviews and writing policy for committee approval. As a newly ACPE-accredited provider

Full access

NCCN News

will perform high-quality clinical trials of emerging therapeutics integrated with evidence-based research in order to guide the use of advanced imaging in clinical cancer care. The SIRC's mission aims to: Establish and standardize new models for

Full access

Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management

Presented by: Aaron T. Gerds

. Gerds. “It is critically important to understand how and why these mutations occur so we can apply this knowledge to our everyday clinics and develop new therapeutics for the future.” Molecular Markers for Diagnosis and Classification As Dr. Gerds

Full access

Building the Palliative Care Evidence Base: Lessons From a Randomized Controlled Trial of Oxygen vs Room Air for Refractory Dyspnea

Thomas W. LeBlanc and Amy P. Abernethy

.; GlaxoSmithKline; Celgene Corporation; Helsinn Therapeutics, Inc.; Dendreon Corporation; KangLaiTe USA; Bristol-Myers Squibb Company; and Pfizer Inc.; these funds are all distributed to Duke University Medical Center to support research including salary support for

Full access

Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess

antitumor efficacy of this regimen. Patients and Methods Study participants were patients seen in the Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) at The University of Texas MD Anderson Cancer Center with a

Full access

Gene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient-Centered Approach

Charles R. Handorf

answered. How will one know when to use newer strategies, and when are the older strategies “good enough”? How will the more expensive diagnostics and therapeutics be paid for in a reimbursement environment that already views medical care as too expensive